Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) EBITDA (2016 - 2025)

Historic EBITDA for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to -$17.5 million.

  • Heron Therapeutics' EBITDA fell 26445.83% to -$17.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.6 million, marking a year-over-year increase of 5123.54%. This contributed to the annual value of -$13.6 million for FY2024, which is 8771.34% up from last year.
  • Heron Therapeutics' EBITDA amounted to -$17.5 million in Q3 2025, which was down 26445.83% from -$2.4 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' EBITDA ranged from a high of $3.6 million in Q4 2024 and a low of -$63.9 million during Q1 2022
  • Its 5-year average for EBITDA is -$28.6 million, with a median of -$25.0 million in 2023.
  • The largest annual percentage gain for Heron Therapeutics' EBITDA in the last 5 years was 18251.02% (2025), contrasted with its biggest fall of 26445.83% (2025).
  • Heron Therapeutics' EBITDA (Quarter) stood at -$54.6 million in 2021, then skyrocketed by 63.71% to -$19.8 million in 2022, then soared by 45.99% to -$10.7 million in 2023, then skyrocketed by 133.95% to $3.6 million in 2024, then crashed by 581.13% to -$17.5 million in 2025.
  • Its EBITDA stands at -$17.5 million for Q3 2025, versus -$2.4 million for Q2 2025 and $2.6 million for Q1 2025.